New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 26, 2012
07:17 EDTAEGRAegerion label for Juxtapid looks favorable, says JPMorgan
JPMorgan views the label for Aegerion's Juxtapid as favorable and reiterates an Overweight rating on the stock after the FDA approved the drug. The firm upped its price target for shares to $30 from $28.
News For AEGR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
16:45 EDTAEGRAegerion sees FY15 global net sales of JUXTAPID $195M-$215M
Subscribe for More Information
16:44 EDTAEGRAegerion reports Q4 adjusted EPS 11c, may not compare to consensus 1c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use